Redeye saw a report that came in more or less as expected.
Paper EBITDA PLN 97m vs. ABGSCe PLN 65m Beat driven by higher volumes and lower costs Early signs of...
Redeye provides an initial take on Enzymatica’s Q3 2023 report.
Redeye sees a solid Q3 report from Hanza, beating our EBITA forecast by 13%.
Cibus posted Q3 net operating income of EUR 31.0m, up 18% y/y but included as much as EUR 2.
With the number of cruise vessel calls down by 51% y/y in Q3, the quarterly results are unlikely to ...
Redeye comments on Better Collective’s acquisition of Playmaker Capital, which is a Toronto-based di...
Redeye saw sales that were in line with our expectations.
Callidita’s strict Tarpeyo (US) product growth is 130% in Q3, and the recorded Q3 sales are 12% belo...
Redeye provides a comment following Faron’s announcement of the initiation of the phase II part of t...
Exel has taken actions to recover earnings. In our view wind power orders should drive at least some...
Redeye provides a preview ahead of Embracer Group’s Q2 2023/24e report, due on 16 November.
SEK 75m from rights issue leads to project re-prioritisation Primary focus on GLP-1 RA space (NEX-22...
Scandinavian Astor Group publicerade den 6 november år 2023 bolagets delårsrapport för tredje kvarta...
Redeye notes Fluoguide announcing phase IIa top-line data with FG001 in head and neck cancer.
Bra Q3-rapport Bolaget gladde igen med att visa starka siffror för det tredje kvartalet.
Redeye comments on Flexion Mobile’s preliminary figures for Q3-Q4 and its revised full year guidance...
Dynava is entrusted by Region Stockholm for an additional two years to operate transportation servic...
Redeye comments on BioInvent’s TNFR2 project BI-1808 after strong phase I results presented at SITC ...
Physitrack will release its Q3 2023 report on 14 November at 08:00 and host a conference call at 10:...
